Business Context and Reporting Period
Company: Scinai Immunotherapeutics Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: September 22, 2025
Context: The filing reports on the status of a grant application submitted by the Company's wholly owned Polish subsidiary. The application sought €12 million in non-dilutive funding under the European Funds for a Modern Economy (FENG) program to support the development of PC111, a monoclonal antibody licensed from Pincell srl for the treatment of pemphigus vulgaris, Stevens-Johnson Syndrome (SJS), and Toxic Epidermal Necrolysis (TEN).
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific corporate development event regarding grant funding.
Material Changes and Events
- Grant Rejection: On September 18, 2025, the National Center for Research and Development in Poland notified the Company that its application for €12 million in funding was not selected.
- Interim Status: The rejection is currently an interim decision. It becomes final only if no appeal is filed within 14 days or if an appeal is ultimately rejected.
- Appeal Filing: The Company intends to file an appeal, arguing that certain project aspects were misconstrued in the initial review.
Outlook, Risks, and Management Commentary
- Timeline: The appeal is expected to be reviewed within approximately one month of submission, with a final determination anticipated before the end of 2025.
- Risk Factors: There is no assurance that the appeal will be successful or that the grant will ultimately be awarded.
- Forward-Looking Statements: The report includes standard warnings that future events may not occur as expected and that the Company undertakes no obligation to update these statements.
Investor Verification Checklist
- Confirm the filing deadline for the appeal (14 days from September 18, 2025) and whether the Company has formally submitted it.
- Monitor for the final determination on the appeal, expected before the end of 2025.
- Assess the impact of the potential loss of €12 million in non-dilutive funding on the Company's cash runway and development timeline for PC111.
- Review the terms of the exclusive license granted to the Polish subsidiary to facilitate the grant application.